Tesamorelin
Choose delivery frequency and start your subscription from your cart — combine multiple products into one subscription if they ship on the same schedule. Free shipping, always. Cancel anytime — one click in your account, no calls, no retention offers.
Concentration calculator
Research summary
Tesamorelin is a synthetic analog of GHRH that stimulates the pituitary to secrete growth hormone, raising IGF-1 in turn. It is an FDA-approved prescription drug under other brand names for a specific indication —a regulatory fact noted here for research-literature context, not a claim about this research-use material.
Across two pooled Phase 3 placebo-controlled trials in HIV-associated lipodystrophy (806 participants), tesamorelin reduced visceral adipose tissue by about 15.4% relative to placebo at 26 weeks. The same trials measured IGF-1 rising roughly 90% and triglycerides falling about 20%. A separate 12-month trial in adults with HIV and fatty liver disease found a greater reduction in liver fat with tesamorelin than placebo.
Sources: Pooled Phase 3 trial analyses; PMC9947601. Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.
Decoding the Benefits
- Visceral fat dropped roughly 15% relative to placebo across two large pooled trials.
- IGF-1 nearly doubled, while triglycerides fell by about a fifth — a combination tied to improved metabolic markers.
- A year-long trial also found measurably less liver fat than placebo in a separate patient group.
Customer reviews
More in Endocrine
